The secret to the ability of a
molecule critical for cell division to throw off the protein yoke that
restrains its activity is the yoke itself -- a disorderly molecule that
seems to have a mind of its own, say investigators at St. Jude Children's
Research Hospital, Innsbruck Medical University (Austria) and Max Planck
Institute (Martinsried, Germany).
A report on the work appears in the January 25 issue of the journal
Cell.
The researchers showed that the disorderly protein yoke, called p27,
participates in its own destruction by swinging the end of its long arm up
into a key side pocket of the cell division molecule called CDK2. After the
end of p27 slips into the pocket, CDK2 marks p27 for destruction by tagging
it with a molecule called phosphate. The tag signals the cell's protein
destruction machinery to dispose of p27, freeing CDK2 to trigger cell
division. However, in order for the long arm of p27 to swing up into the
pocket, an enzyme called a kinase must first remove the upper part of p27
that is lodged in the pocket by tagging it with phosphate. Only then is
there room for the far end of p27 to insert itself.
The findings are important because it explains how CDK2 normally shrugs
off p27 and how some abnormal enzymes cause this to occur prematurely,
putting cell division into overdrive-a state that produces cancer, said
Richard Kriwacki, Ph.D., associate member in the Department of Structural
Biology at St. Jude and co-senior author of the paper.
"The results also show why the anti-cancer drug Gleevec(R) is effective
in treating some forms of leukemia in certain individuals," said Yuefeng
Wang, Ph.D., a postdoctoral student in Kriwacki's laboratory who did much
of the work on this project. "Gleevec blocks the abnormal kinase BCR-ABL
and prevents it from tagging the upper part of p27 lodged in the pocket of
CDK2," he said. "This, in turn, prevents the lower part of p27 from
swinging up into the pocket."
"Blocking the CDK2 pocket after an abnormal kinase dislodges the p27
elbow might be an effective future strategy for preventing cancerous cell
division in these cells," Kriwacki said.
The other authors of the paper are M. Brett Waddell (St. Jude);
Matthias Grimmler, Thomas Mund, Zoran Cilensek, Eva-Maria Keidel, Ludger
Hengst (Max Plank Institute of Biochemistry, Martinsried, Germany) and
Heidelinde Jakel and Michael Kullmann (Innsbruck Medical University,
Innsbruck, Austria. Hengst is also at Innsbruck Medical University).
This work was supported in part by the National Institutes of Health, a
Cancer Center (CORE) Support Grant, ALSAC, Regierung von Oberbayern
(District Government of Upper Bavaria), the Max Planck Society and FWF
(Fund for the Promotion of Scientific Research, Austria).
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for
its pioneering work in finding cures and saving children with cancer and
other catastrophic diseases. Founded by late entertainer Danny Thomas and
based in Memphis, Tenn., St. Jude freely shares its discoveries with
scientific and medical communities around the world. No family ever pays
for treatments not covered by insurance, and families without insurance are
never asked to pay. St. Jude is financially supported by ALSAC, its
fundraising organization. For more information, please visit
stjude/.
St. Jude Children's Research Hospital
stjude/
Комментариев нет:
Отправить комментарий